# US 2025/0367239 A1 · Compositions and methods for non-genotoxic conditioning

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367239 A1
- Document ID: US20250367239A1
- Status: Published application
- Kind: A1
- Application number: 19/107,502
- Filed: 2023-08-29
- Published: 2025-12-04
- Earliest claimed: 2022-08-29
- Assignees: Maro Bio Inc.
- Applicants: Maro Bio Inc.
- Inventors: Akanksha Chhabra; Vanessa Soros; Alan Le
- Web page: https://patentgrep.com/patent/US20250367239A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/10: characterised by the cell type used
- A61K 40/50: characterised by the use of allogeneic cells
- A61P 35/00: Antineoplastic agents
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 5/562: {Temperature processes, e.g. following predefined temperature changes over time}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/8645: {Adeno-associated virus}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/321: 2'-O-R Modification
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods and compositions relating to the use of anti-CD1 10 and anti-CD117 conditioning agents for depletion of endogenous hematopoietic stem cells in a subject, for example. prior to hematopoietic stem cell transplantation. Also provided are cell-based therapy methods and compositions.

## Claims

### Claim 1

A method of hematopoietic stem cell engraftment in a subject in need thereof, the method comprising:
a. depleting endogenous hematopoietic stem cells in the subject by administering to the subject a pharmaceutical composition comprising:
i. a first targeting moiety that specifically binds CD117; and
ii. a second targeting moiety that specifically binds CD110; and
b. administering exogenous hematopoietic stem cells to the subject;
wherein administration of the pharmaceutical composition mediates engraftment of the exogenous hematopoietic stem cells resulting in multi-lineage hematopoietic reconstitution in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first and second moiety bind hematopoietic stem cells co-expressing CD117 and CD110.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the first targeting moiety comprises an isolated antibody or an antigen-binding fragment thereof that specifically binds CD117.

### Claim 4 (depends on 3)

The method of claim 3, wherein the isolated antibody or antigen-binding fragment thereof that specifically binds CD117 functionally disrupts signaling between Stem Cell Factor (SCF) and CD117 and/or mediates clearance of CD117 expressing cells via Fc effector function.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein the second targeting moiety comprises an isolated antibody, or an antigen-binding fragment thereof, that specifically binds CD110.

### Claim 6 (depends on 5)

The method of claim 5, wherein the isolated antibody or antigen-binding fragment thereof that specifically binds CD110 functionally disrupts signaling between Thrombopoietin (TPO) and CD110 and/or mediates clearance of CD110 expressing cells via Fc effector function.

### Claim 7 (depends on 3, 4, 5, 6)

The method of any one of claims 3 to 6, wherein the isolated antibody of the first and/or second targeting moiety is a monoclonal antibody.

### Claim 8 (depends on 3, 4, 5, 6)

The method of any one of claims 3 to 6, wherein the antigen binding fragment of the first and/or second targeting moiety is selected from the group consisting of a Fv fragment, Fab fragment, F(ab′)2 fragment, Fab′ fragment, scFv (sFv) fragment, scFv-Fc fragment, single-chain Fvs (scFv), single-chain antibody, disulfide-linked Fvs (dsFv), fragments comprising either a VL or VH domain, a heavy chain antibody (hcAb), a single domain antibody (sdAb), a minibody, and a variable domain derived from camelid heavy chain antibodies (VHH or nanobody).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein both the first targeting moiety and the second targeting moiety are comprised on the same antibody or antigen binding fragment thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of a diabody, diabody-Fc, single-chain diabody, tandem diabody (Tandab's), tandem scFv, tandem scFv-scFc, tandem di-scFvs, tandem tri-scFvs, multivalent antibody, bivalent or bispecific single chain variable fragment, bispecific IgG and Fab-IgG bispecific.

### Claim 11 (depends on 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 3 to 10, wherein the isolated antibody or antigen binding fragment of the first and/or second targeting moiety comprises an Fc region capable of binding the neonatal Fc receptor (FcRn) of the subject.

### Claim 12 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 3 to 11, wherein the isolated antibody or antigen binding fragment of the first and/or second targeting moiety is chimeric, humanized, or human.

### Claim 13 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 3 to 12, wherein the isolated antibody or antigen binding fragment of the first and/or second targeting moiety comprises a human Fc region.

### Claim 14

A method of hematopoietic stem cell engraftment in a subject in need thereof, the method comprising:
a. depleting endogenous hematopoietic stem cells in the subject by co-administering to the subject:
i. an effective amount of a first isolated antibody, or an antigen-binding fragment thereof, that specifically binds CD117; and
ii. an effective amount of a second isolated antibody, or an antigen-binding fragment thereof, that specifically binds CD110; and
b. administering exogenous hematopoietic stem cells to the subject;
wherein co-administration of the effective amounts of the first and second antibodies, or fragments thereof, synergistically mediates engraftment of the exogenous hematopoietic stem cells resulting in multi-lineage hematopoietic reconstitution in the subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein the first and second isolated antibody, or antigen binding fragments thereof, bind hematopoietic stem cells co-expressing CD117 and CD110.

### Claim 16 (depends on 14, 15)

The method of claim 14 or 15, wherein the first isolated antibody, or antigen-binding fragment thereof, functionally disrupts signaling between Stem Cell Factor (SCF) and CD117 and/or mediates clearance of CD117 expressing cells via Fc effector function.

### Claim 17 (depends on 14, 15, 16)

The method of any one of claims 14 to 16, wherein the second isolated antibody, or antigen-binding fragment thereof, functionally disrupts signaling between Thrombopoietin (TPO) and CD110 and/or mediates clearance of CD110 expressing cells via Fc effector function.

### Claim 18 (depends on 14, 15, 16, 17)

The method of any one of claims 14 to 17, wherein the first isolated antibody and/or the second isolated antibody is a monoclonal antibody.

### Claim 19 (depends on 14, 15, 16, 17)

The method of any one of claims 14 to 17, wherein the first isolated antibody and/or the second isolated antibody is a bispecific antibody.

### Claim 20 (depends on 14, 15, 16, 17, 18, 19)

The method of any one of claims 14 to 19, wherein the antigen binding fragment that specifically binds CD117 is selected from the group consisting of a Fv fragment, Fab fragment, F(ab′)2 fragment, Fab′ fragment, scFv (sFv) fragment, scFv-Fc fragment and nanobody fragment.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 14 to 20, wherein the antigen binding fragment that specifically binds CD110 is selected from the group consisting of a Fv fragment, Fab fragment, F(ab′)2 fragment, Fab′ fragment, scFv (sFv) fragment, scFv-Fc fragment, and nanobody fragment.

### Claim 22 (depends on 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 14 to 21, wherein the Fc region of the first isolated antibody and/or the second isolated antibody is capable of binding the neonatal Fc receptor (FcRn) of the subject.

### Claim 23 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 14 to 22, wherein the first isolated antibody or antigen-binding fragment thereof and/or the second isolated antibody or antigen-binding fragment thereof is chimeric, humanized, or human.

### Claim 24 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 14 to 23, wherein the first isolated antibody or antigen-binding fragment thereof and/or the second isolated antibody or antigen-binding fragment thereof comprises a human Fc region.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1 to 24, wherein the subject is human.

### Claim 26 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 3 to 25, wherein the antibody or antigen-binding fragment thereof that specifically binds CD117 and/or the antibody or antigen-binding fragment thereof that specifically binds CD110 is conjugated to a toxin.

### Claim 27 (depends on 26)

The method of claim 26, wherein the toxin is selected from the group consisting of saporins, saporin derivatives, ricin, abrin, gelonin, momordin, apitoxin, shiga toxins, shiga-like toxins, T-2 mycotoxin, diphtheria toxin, busulfan, pseudomonas exotoxin A, Ricin A chain derivatives, trichosanthin, luffin toxin, maytansine, amatoxin, mechlorethamine, cyclophosphamide, ethylenimine, methylmelamine, methotrexate, fluorouracil, floxuridine, cytarabine, mercaptopurine, azathioprine, thioguanine, fludarabine phosphate, cladribine, dolastatin, auristatin, auristatin E, auristatin F, MMAF, MMAE, MMAD, DMAF, or DMAE, maytansine, DM1 or DM4, duocarmycin, calicheamicin, pyrrolobenzodiazepine, exatecan, and any combination thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1 to 27, further comprising monitoring the subject for depletion of endogenous hematopoietic stem cells prior to administering exogenous hematopoietic stem cells.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1 to 28, wherein the exogenous hematopoietic stem cells are administered to the subject after the first and second isolated antibodies, or antigen-binding fragment(s) thereof, have substantially cleared from the blood of the subject.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1 to 28, wherein the administering of exogenous hematopoietic stem cells to the subject occurs within 3, 5, 7 or 10 days of co-administering the first and second isolated antibodies, or antigen-binding fragment(s) thereof, to the subject.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1 to 30, wherein the exogenous hematopoietic stem cells are allogeneic hematopoietic stem cells.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1 to 30, wherein the exogenous hematopoietic stem cells are autologous hematopoietic stem cells.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1 to 32, wherein the exogenous hematopoietic stem cells comprise CD34+ hematopoietic stem and progenitor cells (HSPCs).

### Claim 34 (depends on 33)

The method of claim 33, wherein the CD34+ HSPCs comprise CD34+/CD38−/CD90+ HSPCs.

### Claim 35 (depends on 134)

The method of claim 134 wherein the CD34+ HSPCs comprise CD34+/CD38−/CD90+/CD45RA-HSPCs.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1 to 35, further comprising one or more of the following steps:
a. collecting a population of hematopoietic stem cells from the subject prior to depletion;
b. culturing the collected population of hematopoietic stem cells; and
c. cryopreserving the collected population of hematopoietic stem cells.

### Claim 37 (depends on 36)

The method of claim 36, wherein collecting the population of hematopoietic stem cells from the subject comprises one or more of the following steps:
a. mobilizing the population of hematopoietic stem cells; and
b. collecting the population of hematopoietic stem cells by apheresis.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1 to 37, wherein the exogenous hematopoietic stem cells are genetically modified.

### Claim 39 (depends on 38)

The method of claim 38, wherein the exogenous hematopoietic stem cells are genetically modified using one or more components of a gene editing system.

### Claim 40 (depends on 39)

The method of claim 39, wherein the one or more components of the gene editing system is selected from the group consisting of: (i) a CRISPR/Cas guide RNA, (ii) a DNA molecule encoding a CRISPR/Cas guide RNA, (iii) a nucleic acid molecule encoding a CRISPR/Cas RNA-guided polypeptide, (iv) a CRISPR/Cas RNA-guided polypeptide, (v) a CRISPR/Cas guide RNA complexed with a CRISPR/Cas RNA-guided polypeptide, (vi) a nucleic acid molecule encoding a zinc finger protein (ZFP), (vii) a ZFP, (viii) a nucleic acid molecule encoding a transcription activator-like effector (TALE) protein, (ix) a TALE protein, and (x) a DNA donor polynucleotide.

### Claim 41 (depends on 40)

The method of claim 40, wherein the CRISPR/Cas RNA-guided polypeptide is a base editor or a prime editor.

### Claim 42 (depends on 39)

The method of claim 39, wherein the one or more components of the gene editing system comprises a nuclease capable of generating a double-strand break within a gene locus of a cell.

### Claim 43 (depends on 42)

The method of claim 42, wherein the one or more components of the gene editing system further comprises a DNA donor polynucleotide.

### Claim 44 (depends on 43)

The method of claim 43, wherein the DNA donor polynucleotide comprises non-overlapping 5′ and 3′ homology arms, wherein each homology arm is homologous to a portion of the gene locus, whereupon generation of the double-strand break within the gene locus by the nuclease, the donor polynucleotide sequence is integrated into the gene locus by homology directed repair (HDR).

### Claim 45 (depends on 39)

The method of claim 39, wherein the gene editing system comprises a CRISPR nuclease and a single guide RNA (sgRNA) capable of hybridizing to a target sequence within the gene locus, wherein the sgRNA guides the CRISPR nuclease to the target sequence.

### Claim 46 (depends on 45)

The method of claim 45, wherein the CRISPR nuclease is a Cas protein.

### Claim 47 (depends on 46)

The method of claim 46, wherein the Cas protein is Cas9 or a high-fidelity variant thereof.

### Claim 48 (depends on 45, 46, 47)

The method of any one of claims 45 to 47, wherein the sgRNA and the CRISPR nuclease are formed in a ribonucleoprotein (RNP) complex.

### Claim 49 (depends on 45, 46, 47, 48)

The method of any one of claims 45 to 48, wherein the sgRNA comprises one or more chemically modified nucleotides.

### Claim 50 (depends on 49)

The method of claim 49, wherein the modified nucleotide is selected from the group consisting of: a 2′-O-methyl nucleotide, a 2′-O-methyl 3′-phosphorothioate nucleotide, and a 2′-O-methyl 3′-thioPACE nucleotide.

### Claim 51 (depends on 49, 50)

The method of claim 49 or 50, wherein a 5′ end, a 3′ end, or a combination thereof of the modified sgRNA comprises a modified nucleotide.

### Claim 52 (depends on 51)

The method of claim 51, further comprising contacting the population of stem cells with an AAV vector comprising a donor polynucleotide sequence.

### Claim 53 (depends on 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 38 to 52, wherein the genetic modification corrects a gene mutation, replaces a mutant allele with a wild-type allele, or inserts a nucleic acid sequence encoding a therapeutic protein

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 1 to 53, wherein the subject suffers from a disease.

### Claim 55 (depends on 54)

The method of claim 54, wherein the disease is a hemoglobinopathy.

### Claim 56 (depends on 55)

The method of claim 55, wherein the hemoglobinopathy is selected from the group consisting of sickle cell disease, α-thalassemia, β-thalassemia, and δ-thalassemia.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 1 to 56, wherein the engraftment occurs in the absence of myeloablative conditioning.

### Claim 58

A method of depleting endogenous hematopoietic stem cells in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising:
a. a first targeting moiety that specifically binds CD117; and
b. a second targeting moiety that specifically binds CD110.

### Claim 59 (depends on 58, 59)

The method of claim 58, wherein administration of the pharmaceutical composition mediates depletion of the exogenous hematopoietic stem cells in the subject. 60 The method of claim 58 or 59, wherein the first and second moiety bind hematopoietic stem cells co-expressing CD117 and CD110.

### Claim 61 (depends on 58, 59, 60)

The method of any one of claims 58 to 60, wherein the first targeting moiety comprises an isolated antibody or an antigen-binding fragment thereof that specifically binds CD117.

### Claim 62 (depends on 58, 59, 60, 61)

The method of any one of claims 58 to 61, wherein the targeting moiety that specifically binds CD117 functionally disrupts signaling between Stem Cell Factor (SCF) and CD117 and/or mediates clearance of CD117 expressing cells via Fc effector function.

### Claim 63 (depends on 58, 59, 60, 61, 62)

The method of any one of claims 58 to 62, wherein the second targeting moiety comprises an isolated antibody, or an antigen-binding fragment thereof, that specifically binds CD110.

### Claim 64 (depends on 63)

The method of claim 63, wherein the isolated antibody or antigen-binding fragment thereof that specifically binds CD110 functionally disrupts signaling between Thrombopoietin (TPO) and CD110 and/or mediates clearance of CD110 expressing cells via Fc effector function.

### Claim 65 (depends on 61, 62, 63, 64)

The method of any one of claims 61 to 64, wherein the isolated antibody of the first and/or second targeting moiety is a monoclonal antibody.

### Claim 66 (depends on 61, 62, 63, 64)

The method of any one of claims 61 to 64, wherein the antigen binding fragment of the first and/or second targeting moiety is selected from the group consisting of a Fv fragment, Fab fragment, F(ab′)2 fragment, Fab′ fragment, scFv (sFv) fragment, scFv-Fc fragment, single-chain Fvs (scFv), single-chain antibody, disulfide-linked Fvs (dsFv), fragments comprising either a VL or VH domain, a heavy chain antibody (hcAb), a single domain antibody (sdAb), a minibody, and a variable domain derived from camelid heavy chain antibodies (VHH or nanobody).

### Claim 67 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 58 to 66, wherein both the first targeting moiety and the second targeting moiety are comprised on the same antibody or antigen binding fragment thereof.

### Claim 68 (depends on 67)

The method of claim 67, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of a diabody, diabody-Fc, single-chain diabody, tandem diabody (Tandab's), tandem scFv, tandem scFv-scFc, tandem di-scFvs, tandem tri-scFvs, multivalent antibody, bivalent or bispecific single chain variable fragment, bispecific IgG and Fab-IgG bispecific.

### Claim 69 (depends on 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 61 to 68, wherein the isolated antibody or antigen binding fragment of the first and/or second targeting moiety comprises an Fc region capable of binding the neonatal Fc receptor (FcRn) of the subject.

### Claim 70 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 61 to 69, wherein the isolated antibody or antigen binding fragment of the first and/or second targeting moiety is chimeric, humanized, or human.

### Claim 71 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 61 to 70, wherein the isolated antibody or antigen binding fragment of the first and/or second targeting moiety comprises a human Fc region.

### Claim 72

A method of depleting endogenous hematopoietic stem cells in a subject in need thereof, the method comprising co-administering to the subject:
a. an effective amount of a first isolated antibody, or an antigen-binding fragment thereof, that specifically binds CD117; and
b. an effective amount of a second isolated antibody, or an antigen-binding fragment thereof, that specifically binds CD110.

### Claim 73 (depends on 72)

The method of claim 72, wherein co-administration of the effective amounts of the first and second antibodies, or fragments thereof, synergistically mediates depletion of the exogenous hematopoietic stem cells in the subject.

### Claim 74 (depends on 72, 73)

The method of claim 72 or 73, wherein the first and second isolated antibody, or antigen binding fragments thereof, bind hematopoietic stem cells co-expressing CD117 and CD110.

### Claim 75 (depends on 2, 15, 60, 74)

The method of any one of claim 2, 15, 60 or 74, wherein the hematopoietic stem cells co-expressing CD117 and CD110 are LT-HSCs.

### Claim 76 (depends on 72, 73, 74, 75)

The method of any one of claims 72 to 75, wherein the first isolated antibody, or antigen-binding fragment thereof, functionally disrupts signaling between Stem Cell Factor (SCF) and CD117 and/or mediates clearance of CD117 expressing cells via Fc effector function.

### Claim 77 (depends on 72, 73, 74, 75, 76)

The method of any one of claims 72 to 76, wherein the second isolated antibody, or antigen-binding fragment thereof, functionally disrupts signaling between Thrombopoietin (TPO) and CD110 and/or mediates clearance of CD110 expressing cells via Fc effector function.

### Claim 78 (depends on 72, 73, 74, 75, 76, 77)

The method of any one of claims 72 to 77, wherein the first isolated antibody and/or the second isolated antibody is a monoclonal antibody.

### Claim 79 (depends on 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 72 to 78, wherein the first isolated antibody and/or the second isolated antibody is a bispecific antibody.

### Claim 80 (depends on 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 72 to 79, wherein the antigen binding fragment that specifically binds CD117 is selected from the group consisting of a Fv fragment, Fab fragment, F(ab′)2 fragment, Fab′ fragment, scFv (sFv) fragment, scFv-Fc fragment and nanobody fragment.

### Claim 81 (depends on 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any one of claims 72 to 80, wherein the antigen binding fragment that specifically binds CD110 is selected from the group consisting of a Fv fragment, Fab fragment, F(ab′)2 fragment, Fab′ fragment, scFv (sFv) fragment, scFv-Fc fragment, and nanobody fragment.

### Claim 82 (depends on 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 72 to 81, wherein the Fc region of the first isolated antibody and/or the second isolated antibody is capable of binding the neonatal Fc receptor (FcRn) of the subject.

### Claim 83 (depends on 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method of any one of claims 72 to 82, wherein the first isolated antibody or antigen-binding fragment thereof and/or the second isolated antibody or antigen-binding fragment thereof is chimeric, humanized, or human.

### Claim 84 (depends on 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 72 to 83, wherein the first isolated antibody or antigen-binding fragment thereof and/or the second isolated antibody or antigen-binding fragment thereof comprises a human Fc region.

### Claim 85 (depends on 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The method of any one of claims 72 to 84, wherein the subject is human.

### Claim 86 (depends on 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any one of claims 72 to 85, wherein the antibody or antigen-binding fragment thereof that specifically binds CD117 and/or the antibody or antigen-binding fragment thereof that specifically binds CD110 is conjugated to a toxin.

### Claim 87 (depends on 86)

The method of claim 86, wherein the toxin is selected from the group consisting of saporins, saporin derivatives, ricin, abrin, gelonin, momordin, apitoxin, shiga toxins, shiga-like toxins, T-2 mycotoxin, diphtheria toxin, busulfan, pseudomonas exotoxin A, Ricin A chain derivatives, trichosanthin, luffin toxin, maytansine, amatoxin, mechlorethamine, cyclophosphamide, ethylenimine, methylmelamine, methotrexate, fluorouracil, floxuridine, cytarabine, mercaptopurine, azathioprine, thioguanine, fludarabine phosphate, cladribine, dolastatin, auristatin, auristatin E, auristatin F, MMAF, MMAE, MMAD, DMAF, or DMAE, maytansine, DM1 or DM4, duocarmycin, calicheamicin, pyrrolobenzodiazepine, exatecan, and any combination thereof.
